|

Immune Checkpoint Inhibitors to Treat Mesothelioma

ByHolly Zink
Immune Checkpoint Inhibitors to Treat Mesothelioma

A new study supports the use of immune checkpoint inhibitors to treat malignant pleural mesothelioma.

The study authors caution that immune checkpoint inhibitors should be used carefully because they can be an expensive treatment.

Immunotherapy for Mesothelioma

Mesothelioma is a rare type of cancer that is caused by exposure to asbestos. It develops from cells of the mesothelium, the lining that covers many of the internal organs of the body. There are approximately 2,000 cases of mesothelioma diagnosed in the United States every year.

Since mesothelioma is so rare, standard treatment options are limited. Standard therapies include chemotherapy, radiation, and surgery. If more than one of these therapies is used, it may be called multimodal therapy.

Immunotherapy has emerged in the last decade as a new treatment option. It is also referred to as biological therapy. It uses the patient’s immune system to treat mesothelioma. Immunotherapy treatment options include vaccine therapy, as well as a treatment that involves an immune cytokine.

Immune checkpoint inhibitors are a form of immunotherapy. One of the reasons mesothelioma tumors can grow out of control is their ability to trick the immune system.

Immune checkpoint inhibitors block mesothelioma’s built-in resistance to immune system attack. They are among the most promising approaches to combating this aggressive cancer. Many studies have been conducted over the last few years to explore this treatment option.

Treatment Response

Italian researchers recently reviewed existing studies on malignant pleural mesothelioma and immune checkpoint inhibitors. The study looked at 17 trials that included a total of over 2,000 patients.

The researchers found that treatments with more than one immune checkpoint inhibitor worked better than treatments with a single immune checkpoint inhibitor. The combined treatment also had a higher rate of negative side effects.

Even though immune checkpoint inhibitors can be effective, it really depends on the patient in question. Not every patient will benefit from this therapy, and it could be costly. The researchers called this “financial toxicity”. They recommend using immune checkpoint inhibitors as a second-line treatment, only if the standard therapies do not work.

Source

Gemelli M, Cortinovis DL, Baggi A, et al. Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: A Systematic Review and Meta-Analysis. Cancers (Basel). 2022;14(24):6063. Published 2022 Dec 9. doi:10.3390/cancers14246063. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775536/

Similar Posts

  • | |

    Mesothelioma Study Finds New Treatment Target

    ByAlex Strauss

    Immunotherapy, which involves reprogramming T-cells to find and attack cancer cells, is one of the fastest-growing areas of cancer research. One of the biggest challenges of immunotherapy is how to harness the power of T-cells against cancer without also turning them against healthy cells. A new study conducted in Switzerland and published in the Journal of Translational Medicine addressed the problem by reprogramming T-cells to recognize and attack mesothelioma cells that express a specific protein. Fibroblast Activation Protein (FAP) is expressed on the surface of tumor-associated fibroblast cells which are found in the connective tissue of mesothelioma tumors. FAP is also found in mesothelioma cells and may play a role in the start of cancer, as well as the growth…

  • | |

    Macrophages May Hold Key to Fighting Mesothelioma

    ByAlex Strauss

    Researchers in Western Australia are investigating new ways of bolstering the immune system in an effort to fight cancers like mesothelioma. Like most types of cancer, malignant mesothelioma occurs primarily in people over 65. That is also the time in life when the immune system typically weakens. Researchers from Curtin University and the University of Western Australia say it is no coincidence that people become more susceptible to mesothelioma as their immunity wanes. In addition to age-related immune dysfunction, mesothelioma patients experience a further decline in immunity caused by the growing tumor itself. To better understand the connection between declining immunity and the onset of mesothelioma, the researchers are focusing on a particular type of immune system cell called a macrophage….

  • | |

    Mesothelioma Study Could Improve Immunotherapy

    ByAlex Strauss

    Scientists have made an important discovery about a component of the immune system that could have an impact on mesothelioma, one of the rarest and most aggressive cancers. Although mesothelioma is rare, it claims about 2,500 lives in the U.S. annually. Scientists around the globe are searching for a method to keep this cancer from spreading across the membranes that surround the lungs or line the abdomen. As mesothelioma tumors on these membranes grow larger, the likelihood that the cancer will spread to the lungs or other internal organs increases. The immune system is designed to help stop the spread of invaders or out-of-control cancer cells. One immune cell, the Natural Killer or NK cell, is known to exert an anti-tumor effect…

  • | |

    Mesothelioma Vaccine Enters Phase 2 Testing

    ByAlex Strauss

    The makers of a new cancer vaccine say they have enrolled the first mesothelioma patients in a study that will combine their drug with chemotherapy against this virulent cancer. The drug, currently known as CRS-207, is manufactured by Aduro Bio Tech, Inc. According to a company press release, CRS-207 is based on an attenuated (made less potent) version of Listeria monocytogenes, bacteria found in soil and water than can cause the food borne illness, Listeriosis. To make CRS-207, scientists at Aduro genetically modified the Listeria monocytogenes in order to produce a powerful immune response against cells that produce mesothelin. Mesothelin is a tumor-associated antigen produced by several types of cancer cells, including mesothelioma cells. Because it works in conjunction with the body’s…

  • |

    Immunotherapy for Mesothelioma Shows Promise

    ByAlex Strauss

    Despite the continuing efforts of researchers around the world, there is currently no standardized cure for mesothelioma. The asbestos-linked cancer is fast-growing and often resistant to conventional therapies. But a growing number of studies have pointed to the value of unconventional treatments like immunotherapy for mesothelioma. Immunotherapy refers to any treatment protocol which aims to harness the body’s own immune system to fight cancer cells.  In a recent article in The Lancet Oncology, two National Cancer Institute researchers summarized some of the most promising immunotherapy approaches now being investigated for mesothelioma: In dendritic cell-based immunotherapy, dendritic cells are harvested from the patient. Outside the body, these cells are stimulated to activate a cytotoxic response against cancer cells.  When they are…

  • | |

    Immunotherapy May Improve Chemotherapy for Mesothelioma

    ByAlex Strauss

    A treatment designed to inhibit a cell protein called CTLA-4 may improve the effectiveness of chemotherapy for mesothelioma. Chemotherapy is considered a front-line treatment for mesothelioma, although it is only moderately effective.  Because mesothelioma is a highly aggressive cancer of the mesothelium, chemotherapy is often used as part of a multimodality therapeutic approach. Increasingly, immunotherapy, which involves manipulation of the genes and immune system, is also part of the treatment approach. CTLA-4 is the name for both a protein and the gene that is responsible for producing it.  A recent published study tested the theory that knocking down cellular production of the CTLA-4 protein could slow tumor growth and stimulate the immune system between rounds of chemotherapy. To test the…